Last 3 Years

2025
130. René, C.A. and R.J. Parks (2025) Extracellular vesicles efficiently deliver survival motor neuron protein to cells in culture. Scientific Reports 15(1):5674.
129. Warman-Chardon, J., B.J. Jasmin, R. Kothary and R.J. Parks (2025) Report on the 6th Ottawa International Conference on Neuromuscular Disease & Biology – September 7-9, 2023, Ottawa, Canada. Journal of Neuromuscular Diseases Vol. 12(1):22143602241304993.

2024
128. Sutton E.R., A. Beauvais, R. Yaworski, Y. De Repentigny, A. Reilly, M.M. Alves de Almeida, M.O. Deguise, K.L. Poulin, R.J. Parks, B.L. Schneider and R. Kothary (2024) Liver SMN restoration rescues the Smn2B/- mouse model of spinal muscular atrophy. EBioMedicine. 110:105444. doi: 10.1016/j.ebiom.2024.105444.
127. Poulin K.L., R.G. Clarkin, J. Del Papa and R.J. Parks (2024) Development and Characterization of an Oncolytic Human Adenovirus-Based Vector Co-Expressing the Adenovirus Death Protein and p14 Fusion-Associated Small Transmembrane Fusogenic Protein. Int J Mol Sci. 25(22):12451. doi: 10.3390/ijms252212451.
126. René C.A. and R.J. Parks (2024) Bioengineering extracellular vesicle cargo for optimal therapeutic efficiency. Mol Ther Methods Clin Dev. 2024 Apr 26;32(2):101259. doi: 10.1016/j.omtm.2024.101259.

2023
125. Boulton S, M.J.F. Crupi, S. Singh, M.E. Carter-Timofte, T. Azad, B.C. Organ, X. He, R. Gill, S. Neault, T. Jamieson, J. Dave, N. Kurmasheva, B. Austin, J. Petryk, R. Singaravelu, B.Z. Huang, N. Franco, K. Babu, R.J. Parks, C.S. Ilkow, D. Olagnier, and J.C. Bell (2023) Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development. J Biol Chem. 299(6):104749. doi: 10.1016/j.jbc.2023.104749.
124. René C.A. and R.J. Parks (2023) Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy. Pharmaceutics 15(6):1764. doi: 10.3390/pharmaceutics15061764.
123. Smith I.C., S. Chakraborty, P.R. Bourque, M.L. Sampaio, G. Melkus, H. Lochmüller, J. Woulfe, R.J. Parks, B. Brais, and J. Warman-Chardon (2023) Emerging and established biomarkers of oculopharyngeal muscular dystrophy. Neuromuscul Disord. 33(11):824-834. doi: 10.1016/j.nmd.2023.09.010.
122. Jennings, M.R. and R.J. Parks (2023) Human adenovirus gene expression and replication is regulated through dynamic changes in nucleoprotein structure throughout infection. Viruses 15(1):161.

2021
121. Han, C.Y., D.A. Patten, S.I. Kim, J.J. Lim, D.W. Chan, M.K.Y. Siu, Y. Han, E. Carmona, R.J. Parks, C. Lee, L.-J. Di, Z. Lu, K.K.L. Chan, J.-L. Ku, E.A. Macdonald, B.C. Vanderhyden, A.-M. Mes-Masson, H.Y.S. Ngan, A.N.Y. Cheung, Y.S. Song, R.C. Bast Jr., M.-E. Harper and B.K. Tsang (2021) Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers 13(14):10.3390/cancers13143399.
120. Clarkin, R., J. Del Papa and R.J. Parks (2021) The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector. Virology 561:87-97.
119. Roberto, J., K.L. Poulin, R.J. Parks and P.O. Vacratsis (2021) Label-free quantitative proteomic analysis of extracellular vesicles released from fibroblasts derived from patients with spinal muscular atrophy Proteomics e2000301. doi: 10.1002/pmic.202000301.
118. Ard, R., J.-C. Maillet, E. Daher, M. Phan, R. Zinoviev, R.J. Parks, and S.H Gee (2021) PKCα-mediated phosphorylation of the diacylglycerol kinase ζ MARCKS domain switches cell migration modes by regulating interactions with Rac1 and RhoA. J Biol Chem. 296:100516. doi: 10.1016/j.jbc.2021.100516.
117. René, C.A. and R.J. Parks (2021) Delivery of therapeutic agents to the central nervous system and the promise of extracellular vesicles. Pharmaceutics 13(4):492. doi: 10.3390/pharmaceutics13040492.
116. Saha, B. and R.J. Parks (2021) Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulators. Virology 555:102-110. doi: 10.1016/j.virol.2020.07.007.
115. Warman Chardon, J., B.J. Jasmin, R. Kothary and R.J. Parks (2021) Report on the 5th Ottawa International Conference on Neuromuscular Disease and Biology - October 17-19, 2019, Ottawa, Canada. Journal of Neuromuscular Diseases. 8(2):323-334. doi: 10.3233/JND-219001.
114. Del Papa, J., R.G. Clarkin, R.J. Parks (2021) Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. Cancer Gene Therapy 28:745-756. doi: 10.1038/s41417-020-0192-9.

All Other Publications

2020
113. Jennings, M.R. and R.J. Parks (2020) Curcumin as an antiviral agent. Viruses 12:1242; doi.org/10.3390/v12111242.
112. Tzelepis, F., H. Kaur Birdi, A. Jirovec, S. Boscardin, C. Tanese de Souza, M. Hooshyar, A. Chen, K. Sutherland, R. Parks, J. Werier, and J.-S. Diallo (2020) Oncolytic rhabdovirus vaccine boosts chimeric anti-DEC205 priming for effective cancer immunotherapy. Molecular Therapy Oncolytics. doi.org/10.1016/j.omto.2020.10.007.
111. Jennings, M.R. and R.J. Parks (2020) Antiviral Effects of Curcumin on Adenovirus Replication. Microorganisms 2020, 8, 1524; doi:10.3390/microorganisms8101524.
110. Saha, B. and R.J. Parks (2020) Recent Advances in Novel Antiviral Therapies against Human Adenovirus. Microorganisms 2020, 8, 1284.
109. Del Papa, J., R.G. Clarkin, R.J. Parks (2020) Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. Cancer Gene Therapy doi: 10.1038/s41417-020-0192-9.
108. Poulin, K.L, E.R. McFall, G. Chan, N.B. Provost, C. Christou, A.C. Smith, R.J. Parks (2020) Fusion of large polypeptides to human adenovirus type 5 capsid protein IX can compromise virion stability and DNA packaging capacity. J Virol. 17;94(17):e01112-20.

2019
107. Saha, B., O. Varette, W.L. Stanford, J.-S. Diallo and R.J. Parks. Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. 2019. Virology 538:24-34.
106. Han, C.Y., D.A. Patten, S.I. Kim, J.J. Lim, M.K.Y. Siu, Y. Han, E. Carmona, R. Parks, C. Lee, K.K. L. Chan7, J.-L. Ku, E.A. Macdonald, B. Vanderhyden, A.M. Mes-Masson, H.Y. S. Ngan, A. Cheung, Y.S. Song, M.-E. Harper and B.K. Tsang. p53 promotes chemoresponsiveness by regulating Hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer. Molecular Carcinogenesis 2019 Sep 4. doi: 10.1002/mc.23106.
105. Zhang, Y., C.Y. Han, F.G. Duan, X.X. Fan, X.J. Yao, R.J. Parks, Y.J. Tang, M.F. Wang, L. Liu, B.K. Tsang, E.L. Leung (2019) p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int. 2019 Jul 19;19:188. doi: 10.1186/s12935-019-0910-2.
104. Del Papa, J., J. Petryk, J.C. Bell, and R.J. Parks (2019) An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo. Molecular Therapy Oncolytics. 14:107-120.
103. Saha, B. and R.J. Parks (2019) Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses human adenovirus gene expression and replication. J Virol. 93(12). pii: e00088-19. doi: 10.1128/JVI.00088-19.

2018
102. Warman Chardon, J., B.J. Jasmin, R. Kothary and R.J. Parks (2018) Report on the 4th Ottawa International Conference on Neuromuscular Disease and Biology - September 5-7, 2017, Ottawa, Canada. Journal of Neuromuscular Diseases. 5(4):539-552.
101. Giberson, A.N., B. Saha, K. Campbell, C. Christou, K.L. Poulin, and R.J. Parks (2018) Human adenoviral DNA association with nucleosomes containing histone variant H3.3 during the early phase of infection is not dependent on viral transcription or replication. Biochem. and Cell. Biol. 96(6):797-807.
100. Parks, R.J. and E. Gussoni (2018) Building immune tolerance through DNA vaccination. Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9652-9654. doi: 10.1073/pnas.1813461115.

2017
99. Nash, L.A, E.R. McFall, A.M. Perozzo, M. Turner, K.L. Poulin, Y. De Repentigny, J.K. Burns, H.J. McMillan, J. Warman Chardon, D. Burger, R. Kothary, and R.J. Parks (2017) Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy. Scientific Reports 7(1):13859.
98. Sundaram, M., K.R. Curtis, M.A. Alipour, N.D. LeBlond, K.D. Margison, R.A. Yaworski, R.J. Parks, A.D. McIntyre, R.A. Hegele, M.D. Fullerton, and Z. Yao (2017) The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. J Lipid Res. 58(11):2188-2196..
97. Eid, W., K. Dauner, K.C. Courtney, A. Gagnon, R.J. Parks, A. Sorisky, and X. Zha. (2017) mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. Proc Natl Acad Sci U S A. 2017 Jul 10. pii: 201705304. doi: 10.1073/pnas.1705304114.
96. Saha, B. and R.J. Parks (2017) Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. PLoS One. 2017 Jul 10;12(7):e0181012.
95. Del Papa, J. and R.J. Parks (2017) Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses 19;9(1). pii: E13. doi: 10.3390/v9010013.

2016
94. Nash, L.A., J.K. Burns, J. Warman Chardon, R. Kothary and R.J. Parks (2016) Spinal Muscular Atrophy: More than a disease of motor neurons? Current Molecular Medicine 16(9):779-792.
93. Alvarez-Saavedra M., Y. De Repentigny, D. Yang, R.W. O'Meara, K. Yan, L.E. Hashem, L. Racacho, I. Ioshikhes, D.E. Bulman, R.J. Parks, R. Kothary, and D.J. Picketts, (2016) Voluntary Running Triggers VGF-Mediated Oligodendrogenesis to Prolong the Lifespan of Snf2h-Null Ataxic Mice. Cell Rep.11:17(3):862-875.
92. Wong, C.M., L.A. Nash, J. Del Papa, K.L. Poulin, T. Falls, J.C. Bell, and R.J. Parks (2016) Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer. Cancer Gene Therapy 23(10):355-364.
91. Warman Chardon, J., B.J. Jasmin, R. Kothary and Parks, R.J., (2016) Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy – September 24-26, 2015, Ottawa, Canada. Journal of Neuromuscular Diseases. 3:431–442.
90. Burns, J.K., R. Kothary and R.J. Parks (2016) Opening the window: The case for carrier and perinatal screening for spinal muscular atrophy. Neuromuscular Disorders 26:551-9.
89. Smethells, J.R., N. Swalve, S. Brimijoin, Y. Gao, R.J. Parks, A. Greer, and M.E. Carroll (2016) Long-term blockade of cocaine self-administration and locomotor activation in rats by an adenoviral vector-delivered cocaine hydrolase. J Pharmacol Exp Ther. 2016 Mar 11. pii: jpet.116.232504.
88. Al-Khalaf, M., L. Blake, B. Larsen, S. Brunette, R. Parks, M. Rudnicki, P. McKinnon, F. Dilworth, R. Bell and L. Megeney (2016) Temporal activation of XRCC1 mediated DNA repair is essential for muscle differentiation. Cell Discovery 2:15041 doi:10.1038/celldisc.2015.41.
87. Wong, C.M., K.L. Poulin, G. Tong, C. Christou, M.A. Kennedy, T. Falls, J.C. Bell and R.J. Parks (2016) Adenovirus-mediated expression of the p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutic efficacy in a xenograft mouse model of cancer PLoS ONE 11(3):e0151516. doi: 10.1371/journal.pone.0151516.

2015
86. Ard, R., K. Mulatz, J.L. Pomoransky, R.J. Parks, L. Trinkle-Mulcahy, J.C. Bell, and S.H. Gee (2015) Regulation of Macropinocytosis by Diacylglycerol Kinase ζ. PLoS ONE 10(12):e0144942. doi: 10.1371/journal.pone.0144942.
85. Chen, V.P., Y. Gao, L. Geng, R.J. Parks, T. Tchkonia, Y.-P. Pang, S. Brimijoin (2015) Plasma butyrylcholinesterase regulates ghrelin to control aggression PNAS 112:2251-6.

2014
84. Saha, B., C.M. Wong, and R.J. Parks (2014) The adenovirus genome contributes to the structural stability of the virion. Viruses 6:3563-3583.
83. McFall, E.R., L.M. Murray, J.A. Lunde, B.J. Jasmin, R. Kothary, and R.J. Parks (2014) A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localized delivery in mice. Virology 468-470:444-453.
82. Murthy, V., Y. Gao, L. Geng, N.K. LeBrasseur, T.A. White, R.J. Parks, and S. Brimijoin (2014) Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. Vaccine 32:4155-62.
81. Puppo, A., G. Cesi, E. Marrocco, P. Piccolo, S. Jacca, D.M. Shayakhmetov, R.J. Parks, B.L. Davidson, S. Colloca, N. Brunetti-Pierri, P. Ng, G. Donofrio, and A. Auricchio (2014) Retinal transduction profiles by high-capacity viral vectors. Gene Therapy 21:855-865.
80. Zlebnik, N.E., S. Brimijoin, Y. Gao, A.T. Saykao, R.J. Parks, and M.E. Carroll (2014) Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology 9:1538-46.
79. Holterman, C., J.-F. Thibodeau, C. Towaij, A. Gutsol, R.J. Parks, M. Cooper, R. Touyz and C. Kennedy (2014) Nephropathy and elevated blood pressure in transgenic mice with podocyte-specific Nox5 expression. Journal of the American Society of Nephrology 25:784-97.

2013
78. von Maltzahn, J., A.E. Jones, RJ. Parks, and M.A. Rudnicki (2013) Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. PNAS 110:16474-9.
77. Geng, L., Y. Gao, X. Chen, S. Hou, C.-G. Zhan, Z. Radic, R.J. Parks, S.J. Russell, L. Pham, and S. Brimijoin (2013) Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One 8(6):e67446.
76. Wong, C.M., E.R. McFall, J.K. Burns and R.J. Parks (2013) The role of chromatin in adenoviral vector function. Viruses 5:1500-1515.
75. Goulet, B.B., R. Kothary and R.J. Parks (2013) Supraphysiological expression of Survival Motor Neuron protein from an adenovirus vector does not adversely affect cell function. Biochemistry and Cell Biology 91(4):252-64.
74. Goulet, B.B., R. Kothary and R.J. Parks (2013) At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression. Current Molecular Medicine 13(7):1160-74.
73. Knipe, D.M., P.M. Lieberman, J.U. Jung, A.A. McBride, K.V. Morris, M. Ott, D. Margolis, A. Nieto, M. Nevels, R.J. Parks and T. Kristie (2013) Snapshots: Chromatin Control of Viral Infection. Virology 435:141-156.

2012
72. Conte, D., M.S. Huh, E. Goodall, M. Delorme, R.J. Parks and D.J. Picketts (2012) Loss of Atrx Sensitizes Cells to DNA Damaging Agents Through p53-Mediated Death Pathways. PLoS One 7(12):e52167
71. Carroll, M.E., N. Zlebnik, J.J. Anker, T. Kosten, F. Orson, X. Shen, B. Kinsey, R.J. Parks, Y. Gao, and S. Brimijoin (2012) Combined Cocaine Hydrolase Gene Transfer and Anti-Cocaine Vaccine Synergistically Block Cocaine-Induced Locomotion. PLoS One 7(8):e43536.
70. Huh, M.S., T. Price-O'Dea, D. Ouazia, B.C. McKay, R.J. Parks, M.A. Rudnicki, and D.J. Picketts (2012) Genomic Instability as a Disease Causing Mechanism in Muscle Specific Atrx Knockout Mice. Journal of Clinical Investigation 122(12):4412-23.
69. Ard, R. H. Abramovici, J.-C. Maillet, A. Fottinger, M. Byham, T.A. Iqbal, A. Yoneda, J.R. Couchman, R.J. Parks, and S.H. Gee (2012) Diacylglycerol kinase-zeta regulates RhoA activation via a kinase-independent scaffolding mechanism. Molecular Biology of the Cell 23(20):4008-19.
68. Anker, J.J., S. Brimijoin, Y. Gao, L. Geng, N.E. Zlebnik, R.J. Parks, and M.E. Carroll (2012) Cocaine hydrolase encoded in viral vectors blocks the reinstatement of cocaine seeking in rats for 6 months. Biological Psychiatry 71:700-5.
67. Giberson, A.N., A.R. Davidson, and R.J. Parks (2012) Chromatin structure of adenovirus DNA throughout infection. Nucleic Acids Res. 40:2369-76.

2011
66. Poulin, K.L., G. Tong, O. Vorobyova, M. Pool, R. Kothary, R.J. Parks (2011) Use of Cre/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX. Virology 420:146–155.
65. Qin, W.¬, M. Sundaram, Y. Wang, H. Zhou, S. Zhong, C.-C. Chang, S. Manhas, E.F. Yao, R.J. Parks, P.J. McFie, S.J. Stone, Z.G. Jiang, C. Wang¬, D. Figeys, W. Jia¬, and Z. Yao (2011) Missense mutation in APOC3 within the C-terminal lipid-binding domain of human apoCIII results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins. J. Biol. Chem. 286:27769-80.
64. Ross, P.J., M.A. Kennedy, C. Christou, M. Risco Quiroz, K.L. Poulin and R.J. Parks (2011) Assembly of helper-dependent adenovirus DNA into chromatin promotes efficient gene expression. J. Virol. 85:3950-3958..
63. Beug, S.T., R.J. Parks, H.M. McBride and V.A. Wallace (2011) Trafficking of the Sonic hedgehog morphogen to the regulated secretory pathway in mammalian neurons. Mol Cell Neurosci 46:583-596.
62. Bamji-Mirza, M., M. Sundaram, S. Zhong, E.F. Yao, R.J. Parks and Z. Yao (2011) Secretion of lipid-poor VLDL particles from McA-RH7777 cells expressing human hepatic lipase. J Lipid Res. 52:540-548.
61. Christou, C., and R.J. Parks (2011) Rational design of murine secreted alkaline phosphatase for enhanced performance as a reporter gene in mouse gene therapy preclinical studies. Human Gene Therapy 22:499-506.

2010
60. Poulin, K.L., R.M. Lanthier, A.C. Smith, C. Christou, M. Risco-Quiroz, K.L. Powell, R.W. O'Meara, R. Kothary, I.A. Lorimer, R.J. Parks (2010) Retargeting of adenovirus vectors through fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol. 84:10074-86.
59. Li, L., S. Wang, A. Jezierski, L. Moalim-Nour, K. Mohib, R.J. Parks, S.F. Retta, L. Wang (2010) A unique interplay between Rap1 and E-cadherin in the endocytic pathway regulates cell fate decisions of human embryonic stem cells. Stem Cells 28:247-57.
58. Boucher, J.G., K.A. Parato, F. Frappier, W. Ma, N. Gajanayaka, R.J. Parks, A. Kumar, J.B Angel (2010) Disparate regulation of LPS-induced MAPK signalling and IL-12p40 expression between different myeloid cell types with and without HIV infection. Viral Immunology 23:17-28.
57. Sundaram, M, S. Zhong, M.-B. Khalil, P.H. Links, Y. Zhao, J. Iqbal, M. Hussain, R.J. Parks, Y. Wang, and Z. Yao (2010) Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid rich conditions. J. Lipid Res. 51:150-161.

2009
56. Finn, J.D., J. Bassett, J.B. Millar, N. Grinshtein, T.C. Yang, R. Parsons, C. Evelegh, Y. Wan, R.J. Parks, and J.L. Bramson (2009) Persistence of transgene expression influences CD8+ T cell expansion and maintenance following immunization with recombinant adenovirus. J. Virol 83:12027-36.
55. Venderova, K., G. Kabbach, E. Abdel-Messih, Y. Zhang, R.J. Parks, Y. Imai, S. Gehrke, J. Ngsee, M.J. LaVoie, R. Slack, Y. Rao, Z. Zhang, B. Lu, M.E. Haque, and D.S. Park (2009) Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Human Molecular Genetics 18:4390-404.
54. Kennedy, M.A. and R.J. Parks (2009) Adenovirus virion stability and the viral genome: size matters. Mol. Ther. 17:1664-1666.
53. Storbeck, C.J., S. Wagner, P. O'Reilly, M. McKay, R.J. Parks, H. Westphal and L.A. Sabourin (2009) The Ldb1 and Ldb2 transcriptional co-factors interact with the Ste20-like kinase SLK and regulate cell migration. Mol. Biol. Cell. 20:4174-4182.
52 Ross, P.J. and R.J. Parks (2009) Construction and characterization of adenovirus vectors. Cold Spring Harbor Protocols doi:.1101/pdb.prot5011
51. Ross P.J., M.A. Kennedy and R.J. Parks (2009) Host cell detection of non-coding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression. J. Virol. 83:8409-17.
50. Abramovici, H., P. Mojtabaie, R.J. Parks, X.-P. Zhong, G.A. Koretzky, M.K. Topham and S.H. Gee (2009) Defective cell migration and membrane ruffling in diacylglycerol kinas?e-z-deficient fibroblasts due to decreased Pak1 phosphorylation and impaired dissociation of Rac1 from its inhibitor RhoGDI. Mol. Biol. Cell. 20:2049-59.
49. Smith, A.C., K.L. Poulin, and R.J. Parks (2009) DNA genome size affects the stability of the adenovirus virion. J. Virol. 83:2025-2028.

2008
48. Muruve, D.A., V.Petrilli, A.K. Zaiss, L.R. White, S.A. Clark, P.J. Ross, R.J. Parks, and J. Tschopp (2008) Recognition of cytosolic microbial and host DNA by the inflammasome triggers an innate immune response. Nature 452:103-107.

2007
47. Deschênes-Furry, J.L., K. Mousavi, F. Bolognani, R.L. Neve, R.J. Parks, N.I. Perrone-Bizzozero, and B.J. Jasmin (2007) The RNA-binding protein HuD binds acetylcholinesterase mRNA in neurons and regulates its gene expression following axotomy. J. Neurosci. 27:665-75.

2006
46. Michaud, J.-L.R., K.M. Chaisson, R.J. Parks, and C.R.J. Kennedy (2006) FSGS-associated mutant alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney International 70:1054-1061.

2005
45. Yakubchyk, Y., H. Abramovici, C. Obagi, R.J. Parks, M.K. Topham, and S.H. Gee (2005) Regulation of neurite outgrowth in N1E-115 cells through spatial control of diacylglycerol kinase-ζ and Rac1 by syntrophins. Molecular and Cellular Biology 25:7181-7192.
44. Deschênes-Furry, J.L., G. Bélanger, J. Mwanjewe, J.A. Lunde, R.J. Parks, N. Perrone-Bizzozero, and B.J. Jasmin (2005) The RNA-binding protein HuR binds to acetylcholinesterase transcripts and regulates their expression in differentiating skeletal muscle cells. Journal of Biological Chemistry 280:25361-25368.
43. Chakkalakal, J.V., J. Thompson, R.J. Parks, and B.J. Jasmin (2005) Molecular, cellular and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J. 19:880-891.
42. Parks, R.J. (2005) Adenovirus protein IX: a new look at an old protein. Molecular Therapy 11:19-25.
41. Maelandsmo, G.M., P.J. Ross, M. Pavliv, R.A. Meulenbroek, C. Evelegh, F.L. Graham, and R.J. Parks (2005) Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice J. Gene Medicine 7:307-315.

2004
40. Brown, R.J., A. Gauthier, R.J. Parks, R. McPherson, D.L. Sparks, J.R. Schultz, and Z. Yao (2004) Severe hypoalphalipoproteinuria in mice expressing human hepatic lipase deficient in binding to heparin sulfate proteoglycan. J. Biol. Chem. 279:42403-42409.
39. Huh, M.S., M.H. Parker, A. Scime, A. Berns, R.J. Parks, and M.A. Rudnicki (2004) Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J. Cell. Biol. 166:865-876.
38. Chambers, K.A., R.J. Parks, and J.B. Angel (2004) Disruption of map kinase activation and nuclear factor binding to the IL-12 p40 promoter in HIV-infected myeloid cells. Clinical and Experimental Immunology 137:329-340.
37. Muruve, D.A., M.J. Cotter, A.K. Zaiss, L.R. White, Q. Liu, T. Chan, S.A. Clark, P.J. Ross, R.A. Meulenbroek, G.M. Maelandsmo, and R.J. Parks (2004) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses J. Virol. 78:5966-5972.
36. Sargent, K.L., R.A. Meulenbroek, and R.J. Parks (2004) Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J. Virol. 78:5032-5037.
35. Meulenbroek, R.M., K.S. Sargent, J. Lunde, B.J. Jasmin, and R.J. Parks (2004) Use of adenovirus pIX to display large polypeptides in the virion – generation of fluorescent virus through the incorporation of pIX-GFP. Mol. Ther. 9:617-624.
34. Bramson, J.L., N. Grinshtein, R.A. Meulenbroek, J. Lunde, D. Kottachchi, I.A. Lorimer, B.J. Jasmin, and R.J. Parks (2004) Helper-dependent adenoviral vectors containing modified fibre for improved transduction of developing and mature muscle cells. Human Gene Therapy 15:179-188.
33. Sargent, K., C. Evelegh, F.L. Graham, and RJ Parks (2004) Development of a size restricted pIX helper virus for amplification of helper dependent adenovirus vectors. Gene Therapy 11:504-511.

2003
32. Ross, P.J. and R.J. Parks (2003) Oncolytic adenovirus: getting there is half the battle. Molecular Therapy 8:705-706.
31. Wellington, C.L., L.R. Brunham, S. Zhou, R. Singaraja, H. Visscher, A. Gelfer, C. Ross, E. James, G. Liu, M. Huber, Y.-Z. Yang, R.J. Parks, A. Groen, J. Najib-Fruchart, and M.R. Hayden (2003) Alterations of plasma lipids in mice via adenoviral mediated hepatic overexpression of human ABCA1. J. Lipid Res. 44:1470-1480.
30. Didonato, C.J., R.J. Parks, and R. Kothary (2003) Development of a gene therapy strategy for the restoration of survival motor neuron (SMN): implications for SMA therapy. Human Gene Therapy 14:179-188.

2002
29. Ng, P., R.J. Parks, and F.L. Graham (2002) Preparation of helper-dependent adenoviral vectors. Methods Mol Med. 2002;69:371-88.
28. Amalfitano, A., and R.J. Parks (2002) Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Current Gene Therapy 2:111-133.
27. Hubberstey, A.V., M. Pavliv and R.J. Parks (2002) Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Therapy 9:321-329.

2001
26. Ng, P., C. Beauchamp, C. Evelegh, R. Parks, and F.L. Graham (2001) Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Molecular Therapy 3:809-815.

2000
25. Parks, R.J. (2000) Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clinical Genetics 58:1-19.
24. Cregan, S.P., J. MacLaurin, T.F. Gendron, S.M. Callaghan, D.S. Park, R.J. Parks, F.L. Graham, P. Morley and R.S. Slack (2000) Helper-dependent adenovirus vectors: their use as a gene delivery system to neurons. Gene Therapy 7:1200-1209.
23. O'Neal, W.K., H. Zhou, N. Morral, C. Langston, R.J. Parks, F.L. Graham, S. Kochanek, A.L. Beaudet (2000) Toxicity associated with repeated administration of first-generation adenoviral vectors is not induced by a helper-dependent vector. Molecular Medicine 6:179-195.
22. Ng, P., R.J. Parks, D.T. Cummings, C.M. Evelegh and F. L. Graham (2000) An enhanced system for construction of adenoviral vectors by the two plasmid rescue method. Hum. Gene Ther. 10:2667-2672.

1999
21. Parks, R.J. and J. L. Bramson (1999) Adenoviral vectors: prospects for gene delivery to the central nervous system. Gene Therapy 6:1349-1350.
20. Parks, R.J., J.L. Bramson, Y. Wan, C.L. Addison, and F.L. Graham (1999) Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J. Virol. 73:8027-8034.
19. Parks, R.J., C.M. Evelegh, and F.L. Graham (1999) Use of helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration. Gene Therapy. 6:1565-1573.
18. Ng, P., R.J. Parks, D. Cummings, C. Evelegh, U. Sankar, and F.L. Graham (1999) A high efficiency Cre/loxP based system for construction of adenoviral vectors. Hum Gene Ther. 10:2667 2672.
17. Morral, N., W. O'Neal, K. Rice, M. Leland, J. Kaplan, P.A. Piedra, H. Zhou, R.J. Parks, R. Velji, E. Aguilar-Cordova, S. Wadsworth, F.L. Graham, S. Kochanek, K.D. Carey, A.L. Beaudet (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96:12816 21.
16. Pastore, L., N. Morral, R. Garcia, H. Zhou, R.J. Parks, S. Kochanek, F.L. Graham, B. Lee, and A.L. Beaudet (1999) Use of tissue-specific promoter reduces immune response to the transgene in adenoviral vectors. Human. Gene Ther. 10:1773-1781.
15. Recchia, A., R.J. Parks, S. Lamartina, C. Toniatti, L. Pieroni, F. Palombo, G. Ciliberto, R. Cortese, N. LaMonica, S. Colloca (1999) Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. USA. 96:2615-2620.

1998
14. Morral, N., R.J. Parks, H. Zhou, C. Langston, G. Scheidner, J. Quinones, F.L. Graham, S. Kochanek and A.L. Beaudet (1998) High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Human Gene Ther. 9:2709 2716.
13. Parks, R.J., C.F. Winchcombe-Forhan, A.M. DeLange, X. Xing and D.H. Evans (1998) DNA ligase gene disruptions can depress viral growth and replication in poxvirus infected cells. Virus Res.56:135 147.
12. Morsy, M.A., M.-C. Gu, S. Motzel, J. Zhao, L. Franlin, J. Lin, H. Allan, R.J. Parks, F.L. Graham, S. Kochanek, A.J. Bett and C.T. Caskey (1998) An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95:7866-7871.
11. Scheidner, G., N. Morral, R.J. Parks, Y. Wu, S.C. Koopmans, C. Langston, F.L. Graham, A.L. Beaudet and S. Kochanek (1998) Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo expression and decreased toxicity. Nature Genet. 8:180-183.

1997
10. Parks, R.J. and F.L. Graham (1997) A helper dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 71:3293 3298.

1996
9. Parks, R.J., L Chen, M. Anton, U. Sankar, M. Rudnicki and F.L. Graham (1996) A helper dependent adenovirus vector system: removal of helper virus by Cre mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93:13565 13570.
8. Parks, R.J. and D.H. Evans (1996) The effect of transcription on genetic recombination in poxvirus-infected cells. Virus Res. 41:11-23.
7. Palaniyar, N., C. Fisher, R. Parks and D.H. Evans (1996) SFV topoisomerase: sequence specificity in a genetically mapped interval. Virol. 221:351-354.

1990-1995
6. Parks, R.J., B. Lichtey, C. Karakis and D.H. Evans (1994) Characterization of the Shope fibroma virus DNA ligase gene. Virol. 202:642-650.
5. Parks, R.J., P.J. Krell, J.B. Derbyshire and E. Nagy (1994) Studies of Fowlpox virus recombination in the generation of recombinant vaccines. Virus Res. 32:283-297.
4. Parks, R.J. and D.H. Evans (1991) Effect of marker distance and orientation on recombinant formation in poxvirus infected cells. J. Virol. 65:1263-1272.
3. Parks, R.J. and D.H. Evans (1991) Marker effects associated with the recom¬bination of insertion and deletion mutations in poxvirus infected cells. Virol. 184:299-309.
2. Fisher, C.A., R.J. Parks, M.L. Lauzon and D.H. Evans (1991) Heteroduplex DNA formation is associated with replication and recombination in poxvirus infected cells. Genetics 129:7-18.
1. Pakuts, A.P., R.J. Parks, C.J. Paul, S.J. Bujaki and R.W. Mueller (1990) Ketoconazole induced hepatic lysosomal phospholipidosis: the effect of concurrent barbiturate treatment. Res. Commun. Chem. Pathol. Pharmacol. 67:55-62.

For more publications use this PubMed ID link.